RxDoctor Payments Data

Timothy Rupnow

Family · Freeport, ILNPI 1699212043

Payments from drug & device makers

$973in general payments, 2019–2025

Across 63 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$137
  • AbbVie$104
  • GSK$102
  • E.r. Squibb & Sons, L.L.C.$84
  • Novo Nordisk$82
  • Biohaven Pharmaceutical Holding Company Ltd.$67
  • plus $398 from 12 others

What the payments were for

  • Food & beverage$973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$973 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$37,553
Medicare patients
131
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$43,051
FarxigaDapagliflozin Propanediol32$39,575
XareltoRivaroxaban26$35,555
OzempicSemaglutide35$33,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,494
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$19,712
MounjaroTirzepatide16$16,050
SymbicortBudesonide/Formoterol Fumarate20$8,819
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$5,399
Semglee (Yfgn) PenInsulin Glargine-Yfgn14$5,343
Breo ElliptaFluticasone/Vilanterol13$5,165
Lyumjev Kwikpen U-100Insulin Lispro-Aabc11$4,894
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,423
Novolog FlexpenInsulin Aspart31$4,282
Advair HfaFluticasone Propion/Salmeterol15$3,987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$15$48,39452 claims
PfizerEliquis$11$43,05134 claims
Johnson & JohnsonXarelto$56$35,55526 claims
Novo NordiskOzempic$82$33,57435 claims
GSKTrelegy Ellipta, Breo Ellipta$102$29,65933 claims
Lilly USA, LLCMounjaro$137$16,05016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,941 family providers in Illinois.

Other family in Freeport

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →